Regeneron Pharmaceuticals (REGN) Stock
Biotech powerhouse using genetics for eye and immune treatments. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in August 2026.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It’s Moving
Regeneron is edging higher as analysts turn more constructive and pipeline news keeps the growth story alive.
- Regeneron’s latest move is being driven more by analyst reassessment than by a single company shock, with several firms lifting targets while keeping views in neutral-to-positive territory.
- The stock also got a lift from a fresh product-and-pipeline narrative, including new development in eye-disease and allergy-related programs that reinforce confidence in long-term growth beyond Dupixent.
- Recent dividend news and ongoing investor attention around a new rare-disease approval have added support, while a pending class-action headline has kept some caution in the mix.
Regeneron is edging higher as analysts turn more constructive and pipeline news keeps the growth story alive.
- Regeneron’s latest move is being driven more by analyst reassessment than by a single company shock, with several firms lifting targets while keeping views in neutral-to-positive territory.
- The stock also got a lift from a fresh product-and-pipeline narrative, including new development in eye-disease and allergy-related programs that reinforce confidence in long-term growth beyond Dupixent.
- Recent dividend news and ongoing investor attention around a new rare-disease approval have added support, while a pending class-action headline has kept some caution in the mix.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for REGN is expected around October 28–29, 2026, based on its recent reporting cadence. This report will cover Q3 2026. For investor planning, that timing aligns with Regeneron’s typical late-October earnings window.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regeneron Pharmaceuticals' stock with a target price of $919.26, indicating growth potential.
Financial Health
Regeneron is performing strongly with impressive profits, high revenue, and substantial cash flow.
Dividend
Regeneron Pharmaceuticals offers a low dividend yield of 0.45%, which may not attract income-focused investors. If you invested $1000, you would be paid $4.50 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
